NASDAQ:KNTE

Kinnate Biopharma (KNTE) Stock Price, News & Analysis

$2.65
-0.01 (-0.38%)
(As of 04/3/2024)
Today's Range
$2.64
$2.68
50-Day Range
$2.27
$2.66
52-Week Range
$1.04
$7.18
Volume
2.81 million shs
Average Volume
418,678 shs
Market Capitalization
$125.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.15

Kinnate Biopharma MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
207.5% Upside
$8.15 Price Target
Short Interest
Healthy
2.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.51) to ($1.25) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.32 out of 5 stars

Medical Sector

117th out of 907 stocks

Biotechnology Industry

1st out of 15 stocks

KNTE stock logo

About Kinnate Biopharma Stock (NASDAQ:KNTE)

Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

KNTE Stock Price History

KNTE Stock News Headlines

KNTE Kinnate Biopharma Inc.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Kinnate Biopharma just downgraded at William Blair, here's why
Wedbush Downgrades Kinnate Biopharma (KNTE)
See More Headlines
Receive KNTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kinnate Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/11/2023
Today
4/24/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:KNTE
Fax
N/A
Employees
84
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.15
High Stock Price Target
$24.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+207.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-116,270,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.06 per share

Miscellaneous

Free Float
27,532,000
Market Cap
$125.13 million
Optionable
Optionable
Beta
1.38
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

KNTE Stock Analysis - Frequently Asked Questions

Should I buy or sell Kinnate Biopharma stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kinnate Biopharma in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" KNTE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KNTE, but not buy additional shares or sell existing shares.
View KNTE analyst ratings
or view top-rated stocks.

What is Kinnate Biopharma's stock price target for 2024?

5 brokerages have issued 12 month price targets for Kinnate Biopharma's stock. Their KNTE share price targets range from $2.00 to $24.00. On average, they predict the company's share price to reach $8.15 in the next year. This suggests a possible upside of 207.5% from the stock's current price.
View analysts price targets for KNTE
or view top-rated stocks among Wall Street analysts.

How have KNTE shares performed in 2024?

Kinnate Biopharma's stock was trading at $2.37 on January 1st, 2024. Since then, KNTE shares have increased by 11.8% and is now trading at $2.65.
View the best growth stocks for 2024 here
.

When is Kinnate Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our KNTE earnings forecast
.

How were Kinnate Biopharma's earnings last quarter?

Kinnate Biopharma Inc. (NASDAQ:KNTE) announced its quarterly earnings data on Thursday, May, 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.73).

When did Kinnate Biopharma IPO?

Kinnate Biopharma (KNTE) raised $170 million in an initial public offering (IPO) on Thursday, December 3rd 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, SVB Leerink, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO.

Who are Kinnate Biopharma's major shareholders?

Kinnate Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Deltec Asset Management LLC (2.20%) and BML Capital Management LLC (1.06%). Insiders that own company stock include Carl L Gordon, James B Tananbaum, Orbimed Advisors Llc and Richard Thomas Williams.
View institutional ownership trends
.

How do I buy shares of Kinnate Biopharma?

Shares of KNTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KNTE) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners